China's Delays In Approving Clinical Trials, Poor IP Protections Block Access To Innovative Drugs - EU Chamber Of Commerce
This article was originally published in The Pink Sheet Daily
Executive Summary
Excellent clinical trial centers and a good medical infrastructure make China well-qualified to better integrate global clinical trials, increase cooperation with world-class clinicians and speed up the regulatory process, according to an EU Chamber position paper.
You may also be interested in...
Protectionist Economic Policies Create Roadblocks For Foreign Companies In China, Says U.S. Treasury Secretary
BEIJING - As the U.S. Senate held hearings on the Chinese exchange rate and overall economic policies that are said to be underlying an immense trade imbalance and blocking American businesses from competing freely in China, Treasury Secretary Timothy Geithner outlined an array of new and potential countermeasures
European Union Chamber Calls For Market Opening, Equal Access In China; €1 Trillion In WTO Procurement At Stake
BEIJING - Nearly a decade after joining the World Trade Organization, which requires all members to provide unfettered access to national markets and equal treatment to foreign and domestic business competitors, China is falling short across many areas, according to the leaders of the European Union Chamber of Commerce in China
Counterfeit Drugs Produced In China Still Threaten Chinese, U.S., Global Consumers
BEIJING - Unless China does more to crack down on counterfeiting and contamination in its pharmaceutical industry, the United States could see a repeat of Chinese-made drugs or raw components causing severe adverse reactions in American hospitals, according to a Washington, D.C.-based scholar